Alessandro Di Federico, Research Fellow at Memorial Sloan Kettering Cancer Center, shared Stephen Liu’s post on X, adding:
“Kudos to Chantal Decroisette et al for conducting the PERSEE study. ORR and PFS better w/ chemo-IO in PD-L1 high;
OS would also probably be statistically significant w/ a larger sample size/longer follow-up, as suggested by our recent meta-analysis.”
Stephen Liu, Chief, Division of Hematology and Oncology at Georgetown Lombardi Comprehensive Cancer Center, shared:
“Off the rousing ESMO26 oral presentation from Dr. Chantal Decroisette, the phase III PERSEE trial with simultaneous publication Annals Oncology.
Combination of chemotherapy + pembrolizumab superior to pembro in PDL1 high NSCLC: PFS 16.1 vs 6.9m, HR 0.56!”
Title: Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020)
Authors: Renaud Descourt, Alice Mogenet, Maelys Consigny, Marie Bernardi, Romain Corre, Olivier Bylicki, Jean-Bernard Auliac, Alain Vergnenègre, Charles Ricordel, Julian Pinsolle, Marie Wislez, Maud Pedrono, Rémi Veillon, Lionel Falchero, Florian Guisier, Pierre-Alexandre Hauss, Acya Bizieux-Thaminy, Stéphane Hominal, Anne Madroszyk, Hubert Curcio, Roland Schott, Eric Huchot, Benjamin Besse, Chrystèle Locher, Jacques Le Treut, Marie-Capucine Willemin, Géraldine François, Arnaud Uguen, Maurice Pérol, Christos Chouaïd, Laurent Greillier, Chantal Decroisette
You can also read:
PERSEE Trial: Pembrolizumab With or Without Chemotherapy in PD-L1–High NSCLC
